var data={"title":"Hepatitis B immune globulin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hepatitis B immune globulin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6310?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hepatitis-b-immune-globulin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hepatitis B immune globulin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=hepatitis-b-immune-globulin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Hepatitis B immune globulin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178933\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>HepaGam B;</li>\n      <li>HyperHEP B S/D;</li>\n      <li>Nabi-HB</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178934\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>HepaGam B;</li>\n      <li>HyperHEP B S/D</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178944\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Blood Product Derivative;</li>\n      <li>\n        Immune Globulin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178935\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postexposure prophylaxis:</b> IM: 0.06 mL/kg as soon as possible after exposure (ie, within 24 hours of needlestick, ocular, or mucosal exposure or within 14 days of sexual exposure); repeat at 28 to 30 days after exposure in non-responders to hepatitis B vaccine or in patients who refuse vaccination</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Postexposure management of health care personnel (HCP)</b> (CDC 62 [10], 2013): IM: 0.06 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If the HCP has prior documentation of &ge;3 doses of a hepatitis B vaccine and a post-vaccination anti-HBs &ge;10 milliunits/mL, then HBIG is not needed, regardless of the patients HBsAg status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If the HCP is unvaccinated or incompletely vaccinated, and if the source patient is HBsAG positive or their status is unknown, one dose HBIG should be administered. If the source patient is HBsAG negative, then HBIG is not needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If the HCP is vaccinated with 3 doses of hepatitis B vaccine but post-vaccination anti-HBs status is unknown, test HCP for anti-HBs. If anti-HBs &ge;10 milliunits/mL then HBIG is not needed. If anti-HBs &lt;10 milliunits/mL, and if the source patient is HBsAG positive or their status is unknown, 1 dose of HBIG should be administered. If anti-HBs &lt;10 milliunits/mL, and if the source patient is HBsAG negative, then HBIG is not needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If the HCP is vaccinated with 6 doses of hepatitis B vaccine but documented as a non-responder to the vaccine, and if the source patient is HBsAG negative, then HBIG is not needed. If the source patient is HBsAG positive or unknown, administer 2 doses of HBIG separated by 1 month.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Prevention of hepatitis B virus recurrence after liver transplantation (HepaGam B):</b> IV: 20,000 units/dose according to the following schedule:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Anhepatic phase (Initial dose): One dose (20,000 units) given with the liver transplant</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Week 1 postop: One dose (20,000 units) daily for 7 days (days 1 to 7)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Weeks 2-12 postop: One dose (20,000 units) every 2 weeks starting day 14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Month 4 onward: One dose (20,000 units) monthly starting on month 4</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dose adjustment: Adjust dose to reach anti-HBs levels of 500 units/L within the first week after transplantation. In patients with surgical bleeding, abdominal fluid drainage &gt;500 mL or those undergoing plasmapheresis, administer 10,000 units/dose every 6 hours until target anti-HBs levels are reached.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178941\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=hepatitis-b-immune-globulin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Hepatitis B immune globulin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Infants born to HBsAg-positive mothers: </b> IM: 0.5 mL as soon after birth as possible (within 12 hours); active vaccination with hepatitis B vaccine may begin at the same time in a different site (if not contraindicated). If first dose of hepatitis B vaccine is delayed for as long as 3 months, dose may be repeated. If hepatitis B vaccine is refused, dose may be repeated at 3 and 6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Infants born to mothers with unknown HBsAg status at birth (CDC 2005):</b> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Birth weight &lt;2 kg: 0.5 mL within 12 hours of birth (along with hepatitis B vaccine) if unable to determine maternal HBsAg status within that time</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Birth weight &ge;2 kg: If the mother is determined to be HBsAg positive, administer 0.5 mL as soon as possible, but within 7 days of birth</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Household exposure prophylaxis in infants &lt;12 months:</b> IM: 0.5 mL (to be administered if mother or primary caregiver has acute HBV infection).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postexposure prophylaxis:</b> IM: Children &ge;12 months: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> HBIG may be administered at the same time (but at a different site) or up to 1 month preceding hepatitis B vaccination without impairing the active immune response</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178936\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897466\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897467\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178920\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HepaGam B:  (1 mL, 5 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HyperHEP B S/D:  (0.5 mL, 1 mL, 5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nabi-HB:  (1 mL, 5 mL) [thimerosal free]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178907\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178923\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HBIG may be administered at the same time (but at a different site) or up to 1 month preceding hepatitis B vaccination without impairing the active immune response</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Post-exposure prophylaxis: IM injection only in anterolateral aspect of upper thigh and deltoid muscle of upper arm; to prevent injury from injection, care should be taken when giving to patients with thrombocytopenia or bleeding disorders</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HepaGam B: Liver transplant: Administer at 2 mL/minute. Decrease infusion to &le;1 mL/minute for patient discomfort or infusion-related adverse events. Actual volume of infusion is dependent upon potency labeled on each individual vial.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nabi-HB: Although not FDA-approved for this purpose, Nabi-HB has been administered intravenously in hepatitis B-positive liver transplant patients (Dickson 2006)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178921\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Post-exposure prophylaxis following acute exposure to hepatitis B surface antigen (HBsAg) blood, plasma, or serum (eg, parenteral exposure, direct mucus membrane contact, oral ingestion); perinatal exposure of infants born to HBsAg-positive mothers; sexual exposure to HBsAg-positive persons; and household exposure to persons with acute HBV infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prevention of hepatitis B virus recurrence after liver transplantation in HBsAg-positive transplant patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Hepatitis B immune globulin is not indicated for treatment of active hepatitis B infection and is ineffective in the treatment of chronic active hepatitis B infection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6052749\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">HBIG may be confused with BabyBIG</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Bayhep-B [Philippines, Turkey] may be confused with Bayrab which is a brand name for rabies immune globulin [Philippines, Turkey]; Bayrho-D which is brand name for Rh<sub>o</sub>D immune globulin [Israel, Turkey] </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178914\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Reported with postexposure prophylaxis. Adverse events reported in liver transplant patients included tremor and hypotension, were associated with a single infusion during the first week of treatment, and did not recur with additional infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypotension (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Malaise (6%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Ecchymoses (2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (2% to 4%), vomiting (2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Change in WBC count (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum alkaline phosphatase (4%), increased liver enzymes (2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Pain at injection site (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Myalgia (10%), joint stiffness (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Increased serum creatinine (2%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, anaphylactic reaction (rare), angioedema, back pain, chills, diaphoresis, dizziness, dyspnea, fever, flu-like symptoms, hypersensitivity, increased serum lipase, increased serum transaminases, sinus tachycardia, tenderness at injection site, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178926\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HepaGam B: Anaphylactic or severe systemic reaction to human globulin preparations; IgA deficiency; postexposure prophylaxis in patients with severe thrombocytopenia or other coagulation disorders which would contraindicate IM injections (administer only if benefit outweighs the risk)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HyperHEP B S/D: No contraindications listed in manufacturer's labeling</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabi-HB: Anaphylactic or severe systemic reaction to human globulin preparations</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178911\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; immediate treatment (including epinephrine 1 mg/mL) should be available. Use with caution in patients with isolated immunoglobulin A deficiency or a history of systemic hypersensitivity to human immunoglobulins.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: When administered IV, do not exceed recommended infusion rates; may increase risk of adverse events. Patients should be monitored for adverse events during and after the infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic events: Thrombotic events have been reported with administration of intravenous immune globulin; use with caution in patients of advanced age, with a history of atherosclerosis or cardiovascular and/or thrombotic risk factors, patients with impaired cardiac output, coagulation disorders, prolonged immobilization, or patients with known/suspected hyperviscosity. Consider a baseline assessment of blood viscosity in patients at risk for hyperviscosity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with thrombocytopenia or coagulation disorders; IM injections may be contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Maltose: Some products may contain maltose, which may result in falsely-elevated blood glucose readings.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299441\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178915\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8520&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Consult full interaction monograph for dose interval recommendations.  This interaction does not apply to oral Ty21a typhoid vaccine or others listed as exceptions.<b> Exceptions: </b>Influenza Virus Vaccine (Live/Attenuated); Rotavirus Vaccine; Yellow Fever Vaccine; Zoster Vaccine (Live/Attenuated).<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178917\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2530309\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Use of HBIG is not contraindicated in pregnant women and may be used for postexposure prophylaxis when indicated (CDC 2001). In addition, use of HBIG has been evaluated to reduce maternal to fetal transmission of hepatis B virus during pregnancy (ACOG 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4603416\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if immune globulin from these preparations is excreted into breast milk. The manufacturer recommends that caution be used if administered to breastfeeding women. Endogenous immune globulins can be found in breast milk (Agarwal 2011). Infants born to HBsAg-positive mothers may be breast fed (CDC 2005). Use of HBIG is not contraindicated in breastfeeding women (CDC 2001).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4603420\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver transplant: Serum HBsAg; LFTs; infusion-related adverse events</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178910\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Hepatitis B immune globulin (HBIG) is a nonpyrogenic sterile solution containing immunoglobulin G (IgG) specific to hepatitis B surface antigen (HBsAg). HBIG differs from immune globulin in the amount of anti-HBs. Immune globulin is prepared from plasma that is not preselected for anti-HBs content. HBIG is prepared from plasma preselected for high titer anti-HBs. In the US, HBIG has an anti-HBs high titer &gt;1:100,000 by IRA.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178925\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Postexposure prophylaxis: 3 to 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: IM: Slow</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life: 17 to 25 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 7 to 15 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IM: 2 to 10 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178928\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bayhep (PK);</li>\n      <li>Euvax-B (KR);</li>\n      <li>Fovepta (VN);</li>\n      <li>Hebagam IM (ZA);</li>\n      <li>Hep-B Gammagee (AE);</li>\n      <li>HepaBig (EG);</li>\n      <li>Hepabig (IN, KR, MY, PH);</li>\n      <li>Hepacaf (BE);</li>\n      <li>Hepagam B (IL);</li>\n      <li>Hepatect (AT, CH, CO, DE, EE, ES, HN, IE, NO, PL, PT, QA, TR, TW);</li>\n      <li>Hepatect CP (VN);</li>\n      <li>Hepatitis B Immunoglobulin-VF (AU);</li>\n      <li>HepBQuin (IN, NL);</li>\n      <li>Hepuman Berna (PE);</li>\n      <li>Hyperhep (QA);</li>\n      <li>HyperHEP B (HK, IL, NZ, TW);</li>\n      <li>Igantibe (ID);</li>\n      <li>IMMUNOHBs (TH);</li>\n      <li>IVheBex (FR, GR);</li>\n      <li>NEOHepatect (CZ);</li>\n      <li>Niuliva (SG);</li>\n      <li>VENBIG (DK, TH);</li>\n      <li>Zutectra (GB, IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Agarwal S, Karmaus W, Davis S, Gangur V.  Immune markers in breast milk and fetal and maternal body fluids: a systematic review of perinatal concentrations. <i>J Hum Lact</i>. 2011;27(2):171-186.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-drug-information/abstract-text/21678611/pubmed\" target=\"_blank\" id=\"21678611\">21678611</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, ACOG Practice Bulletin No. 86: &ldquo;Viral Hepatitis in Pregnancy,&rdquo; <i>Obstet Gynecol</i>, 2007, 110(4):941-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-drug-information/abstract-text/17906043/pubmed\" target=\"_blank\" id=\"17906043\">17906043</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part I: Immunization of Infants, Children, and Adolescents,&rdquo; <i>MMWR Recomm Rep</i>, 2005, 54(RR-16):1-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-drug-information/abstract-text/16371945/pubmed\" target=\"_blank\" id=\"16371945\">16371945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of Adults,&rdquo; <i>MMWR Recomm Rep</i>, 2006, 54(RR-16):1-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-drug-information/abstract-text/17159833/pubmed\" target=\"_blank\" id=\"17159833\">17159833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management. <i>MMWR Recomm Rep</i>. 2013;62(RR-10):1-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-drug-information/abstract-text/24352112/pubmed\" target=\"_blank\" id=\"24352112\">24352112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), U.S. Public Health Service, &quot;Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis,&quot; <i>MMWR Recomm Rep</i>, 2001, 50(RR-11):1-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-drug-information/abstract-text/11442229/pubmed\" target=\"_blank\" id=\"11442229\">11442229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo; <i>Am J Health-Syst Pharm</i>, 2007, 64(16):1711-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dickson RC, Terrault NA, Ishitani M, et al, &ldquo;Protective Antibody Levels and Dose Requirements for IV 5% Nabi Hepatitis B Immune Globulin Combined With Lamivudine in Liver Transplantation for Hepatitis B-Induced End Stage Liver Disease,&rdquo; <i>Liver Transpl</i>, 2006,  12(1):124-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-drug-information/abstract-text/16382463/pubmed\" target=\"_blank\" id=\"16382463\">16382463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HepaGam B (hepatitis B immune globulin intravenous [human]) [prescribing information]. Berwyn, PA: Aptevo BioTherapeutics LLC; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tung BY and Kowdley KV, &ldquo;Hepatitis B and Liver Transplantation,&rdquo; <i>Clin Infect Dis</i>, 2005, 41(10):1461-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-b-immune-globulin-drug-information/abstract-text/16231258/pubmed\" target=\"_blank\" id=\"16231258\">16231258</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8520 Version 122.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F178933\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F178934\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F178944\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F178935\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F178941\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F178936\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15897466\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15897467\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F178920\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F178907\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F178923\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F178921\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6052749\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F178914\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F178926\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F178911\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299441\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F178915\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F178917\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2530309\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F4603416\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F4603420\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F178910\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F178925\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F178928\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8520|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hepatitis-b-immune-globulin-patient-drug-information\" class=\"drug drug_patient\">Hepatitis B immune globulin: Patient drug information</a></li><li><a href=\"topic.htm?path=hepatitis-b-immune-globulin-pediatric-drug-information\" class=\"drug drug_pediatric\">Hepatitis B immune globulin: Pediatric drug information</a></li></ul></div></div>","javascript":null}